Log inSign up
user avatar
Alzamend Neuro, Inc.
@AlzamendNeuro
Clinical-stage biopharmaceutical company focused on the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Nasdaq $ALZN
Atlanta, GA
Alzamend.com
Joined February 2016
1,881
Following
1,424
Followers
  • Pinned
    user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Mar 26
    Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 “Lithium in Brain” Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions #Bipolar #Depression #PTSD #Alzheimers #lithium $ALZN
    Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in...
    From ir.alzamend.com
    558
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    May 5, 2022
    Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s #Alzheimers #depression #bipolar #PTSD $ALZN
    Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001...
    From ir.alzamend.com
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Dec 12, 2021
    Please see the press release: Top line data this month for our drug AL001 in humans trials. $ALZN #AlzheimersDisease businesswire.com/news/home/2021…
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Aug 15, 2022
    AL001 is currently in Phase IIA trials and we aim to submit a IND to the FDA for AL002 in September 2022. #Alzheimers #bipolardisorder #depression #ptsd #clinicaltrials $ALZN
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Sep 20, 2022
    AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate for the treatment of Alzheimer’s Disease, Bipolar Disorder, Major Depressive Disorder, and PTSD which is currently in Phase IIA trials. #ENDALZ $ALZN
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Sep 29, 2022
    Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type #Alzheimers #ENDALZ $ALZN
    Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to...
    From ir.alzamend.com
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Nov 29, 2022
    ALZN002 is an adjuvant-free therapeutic "active" vaccine designed for the treatment and prevention of Alzheimer’s Disease. Last month we received a “Study May Proceed” Letter from the FDA to begin our Phase 1/IIA clinical trial. #Alzheimers #ENDALZ $ALZN
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Jul 27, 2022
    The novel ionic cocrystal of lithium (AL001), which was designed, synthesized and characterized by a team of inventors from the University of South Florida has been shown to exhibit improved nonclinical pharmacokinetics compared to currently FDA-approved lithium products. $ALZN
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Jun 7, 2023
    Topline data for the AL001 Phase IIA Multiple Ascending Dose Study will not only ascertain the highest tolerable dosage for Alzheimer's patients & allow further Phase II studies, it will also provide the data to submit the 3 additional IND's for #BipolarDisorder #MDD #PTSD. $ALZN
    4.7K
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Sep 19, 2022
    #Alzheimers #bipolardisorder #depression #ptsd #clinicaltrials $ALZN
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Oct 5, 2022
    Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects #Alzheimers #Bipolar #Depression #PTSD $ALZN
    Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001...
    From ir.alzamend.com
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Nov 17, 2022
    A great experience for Alzamend CEO Stephan Jackman to be interviewed by @cvpayne on @FoxBusiness yesterday and spread the word about our science and pipeline #Alzheimers #bipolar #depression #PTSD $ALZN @alzassociation youtu.be/CEuPU-hM0us
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Oct 6, 2022
    AL001 is a lithium-salicylate-L-proline engineered ionic co-crystal currently in Phase IIA trials with Alzheimer's patients and healthy subjects. Phase I trial demonstrated bioequivalence for half the dosage of lithium carbonate. #alzheimers #bipolar #depression #ptsd $ALZN
  • user avatar
    Alzamend Neuro, Inc.
    @AlzamendNeuro
    Sep 30, 2022
    This week we submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for our immunotherapy product candidate ALZN002. #Alzheimers #ENDALZ $ALZN